Let's Chat About GI Cancers

Article

Join us on Tuesday, April 10 at 1 p.m. EST for our monthly #CureConnect tweet chat, where we’ll focus on our recent gastrointestinal cancers special issue.

The world of gastrointestinal (GI) cancers is rapidly changing, and we would love to hear from our readers about it — whether you are 10 years with no evidence of disease or just starting out treatment.

Join us on Tuesday, April 10 at 1 p.m. EST for our monthly #CureConnect tweet chat, where we’ll focus on our recent gastrointestinal cancers special issue.

We will discuss the boom of immunotherapy in the field, which is providing great outcomes for patients whose tumors are classified as microsatellite instability-high (MSI-H). But with immunotherapy treatment comes a new class of side effects and things to look out for during treatment.

But immunotherapy is not the only major advance that we’ll talk about. Chemotherapy and new surgery techniques are still providing benefit for many GI cancer types, as presented in the 2018 Gastrointestinal Cancers Symposium.

Finally, we’ll discuss selfless acts and amazing feats that help to continue to move the field of GI cancers forward. We will reflect on the generosity of the late Cindy Stowell who won more than $100,000 on Jeopardy! However, shortly after appearing on the game show, Stowell passed away from colorectal cancer, and left her earnings to fund immunotherapy research.

We’d love to hear about your experiences with GI cancers — be it as a patient, survivor or caregiver. See you on Tuesday!

Related Videos
Video 8 - "Acalabrutinib-Based Treatment Clinical Trial Updates"
Video 7 - "Overview of Efficacy and Safety Data for Current CLL Treatment Options"
Image of Kristen Dahlgren at Extraordinary Healer.
Image of Kathy Mooney
Josie Montegaard, MSN, AGPCNP-BC, an expert on CLL
Yuliya P.L Linhares, MD, an expert on CLL
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"